Interpace Biosciences: Gains on plans of collaborative study for diagnostic test

Interpace Biosciences

06/01/2020 13:01

** Diagnostics company's  IDXG.O  shares up 5.7% at $0.55
premarket 
    ** IDXG enters a collaborative study with the University of
North Carolina to assess the use of its product, BarreGEN, to
help patients undergoing cancer preventative therapy for
Barrett's Esophagus
    ** Barrett's Esophagus is a disease that affects the food
pipe
    ** Study expected to begin enrolling patients early Q1 with
and readout later in the year
    ** Stock posted its 7th consecutive annual percentage loss
in 2019

 (Reporting by Medha Singh in Bengaluru)
 ((medha.singh@thomsonreuters.com))